Ascendis Pharma Files 6-K for June 30, 2025
Ticker: ASND · Form: 6-K · Filed: Aug 7, 2025 · CIK: 1612042
Sentiment: neutral
Topics: financial-update, sec-filing, pharmaceutical
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) 6-K filed: Financials updated as of 06/30/2025. Check for performance details.
AI Summary
Ascendis Pharma A/S filed a 6-K report as of June 30, 2025. The filing includes financial data and details related to its operations, such as issued capital and financial liabilities at amortized cost. It also references specific dates like September 3, 2024, and June 30, 2024, for various financial reporting elements.
Why It Matters
This filing provides an update on Ascendis Pharma's financial position and operational metrics as of mid-2025, which is crucial for investors tracking the company's performance.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing an update on the company's financial status and does not appear to contain significant new risks or material adverse events.
Key Numbers
- 2025-06-30 — Reporting Period End Date (Indicates the end of the financial period covered by the report.)
- 2025-08-07 — Filing Date (The date the report was officially submitted to the SEC.)
Key Players & Entities
- Ascendis Pharma A/S (company) — Filer of the 6-K report
- June 30, 2025 (date) — Conformed period of report
- August 7, 2025 (date) — Filed as of date
- September 3, 2024 (date) — Referenced date for Royalty Pharma United States Yorvipath
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing serves as a periodic report by Ascendis Pharma A/S to provide updated financial information and operational details as of June 30, 2025.
What specific financial elements are mentioned in the filing for the period ending June 30, 2025?
The filing mentions 'IssuedCapitalMember', 'FinancialLiabilitiesAtAmortisedCostMember', and 'LaterThanOneYearAndNotLaterThanFiveYearsMember' for the period ending June 30, 2025.
Are there any specific past dates referenced in the filing?
Yes, the filing references September 3, 2024, in relation to 'RoyaltyPharmaUnitedStatesYorvipathMember' and June 30, 2024, for 'ReserveOfExchangeDifferencesOnTranslationMember' and 'TreasurySharesMember'.
What is the company's fiscal year end?
Ascendis Pharma A/S's fiscal year ends on December 31.
What is the company's primary business classification according to the SIC code?
Ascendis Pharma A/S is classified under 'Pharmaceutical Preparations' with SIC code 2834.
Filing Stats: 4,422 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-08-07 16:16:37
Filing Documents
- asnd-20250630.htm (6-K) — 2390KB
- img149484073_0.jpg (GRAPHIC) — 82KB
- img149484073_1.jpg (GRAPHIC) — 149KB
- img149484073_2.jpg (GRAPHIC) — 94KB
- img149484073_3.jpg (GRAPHIC) — 58KB
- img149484073_4.jpg (GRAPHIC) — 67KB
- img149484073_5.jpg (GRAPHIC) — 188KB
- img149484073_6.jpg (GRAPHIC) — 83KB
- img149484073_7.jpg (GRAPHIC) — 125KB
- img149484073_8.jpg (GRAPHIC) — 60KB
- img149484073_9.jpg (GRAPHIC) — 57KB
- img149484073_10.jpg (GRAPHIC) — 30KB
- 0001612042-25-000006.txt ( ) — 10165KB
- asnd-20250630.xsd (EX-101.SCH) — 1098KB
- asnd-20250630_htm.xml (XML) — 1417KB
Financial Statements
Financial Statements This report contains the Company's Unaudited Condensed Consolidated Interim Financial Statements as of and for the period ended June 30, 2025, including Management's Discussion and Analysis of Financial Condition and Results of Operations for the period presented therein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: August 7, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer TABLE OF CONTENTS 1. Unaudited Condensed Consolidated Interim Financial Statements – June 30, 2025 F- 1 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 1 ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three and Six Months Ended June 30, 2025 and 2024 F-2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2025 and December 31, 2024 F-3 Unaudited Condensed Consolidated Interim Statements of Changes in Equity as of June 30, 2025 and 2024 F-4 Unaudited Condensed Consolidated Interim Cash Flow Statements for the Six Months Ended June 30, 2025 and 2024 F-5 Notes to the Unaudited Condensed Consolidated Interim Financial Statements F-6 F- 1 Unaudited Conden sed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three and Six Months Ended June 30, 2025 and 2024 Three Months Ended June 30, Six Months Ended June 30, (EUR'000, except per share data) Notes 2025 2024 2025 2024 Consolidated Statement of Profit or (Loss) Revenue 5 158,045 35,998 258,998 131,892 Cost of sales 31,447 11,465 48,963 19,034 Gross profit 126,598 24,533 210,035 112,858 Research and development expenses 71,988 83,478 158,591 154,165 Selling, general, and administrative expenses 107,561 74,312 208,608 141,095 Operating profit/(loss) ( 52,951 ) ( 133,257 ) ( 157,164 ) ( 182,402 ) Share of profit/(loss) of associates 4 ( 4,097 ) ( 5,322 ) 22,482 ( 11,118 ) Finance income 55,059 49,052 83,912 14,395 Finance expenses 33,018 19,624 77,803 58,553 Profit/(loss) before tax ( 35,007 ) ( 109,151 ) ( 128,573 ) ( 237,678 ) Income taxes (expenses) ( 3,848 ) ( 229 ) ( 4,909 ) ( 2,737 ) Net profit/(loss) for the period ( 38,855 ) ( 1